Posts
February 02 2017
Rennova Health, Inc. announced the closing of their Registered Direct offering in the amount of $1,500,000. EG&S acted as counsel to the Investor.
January 31 2017
The Ninth Circuit has dismissed an appeal by a group of shareholders who had accused Cellular Biomedicine Group in a federal class action of inflating its stock price through a promotional scheme. Plaintiffs chose not to challenge the district court’s holding that they could not allege loss causation.
Adrienne M. Ward and Michael J. Sullivan, both members of the Firm, represented Cellular Biomedicine in the appeal. Click here to read more on the case.
January 30 2017
The February 2017 edition of Westchester Lawyer Magazine includes an article by James K. Landau, a member in the Firm’s litigation department, entitled “How to Leverage the Internet and Technology to Sharpen your Appellate Advocacy”. Mr. Landau is the co-chair of the Westchester County Bar Association’s Committee on Appellate Practice and handles cases involving misappropriation of trade secrets, non-competition clauses in employment agreements and real estate related litigation. The article can be read here.
January 27 2017
BioAmber Inc. announced the closing of their Underwritten offering in the amount of $20,125,009. EG&S acted as counsel to the Underwriter.
January 25 2017
Fintech Acquisition Corp. II announced the closing of their initial public offering in the amount of $153,000,000. EG&S acted as counsel to Cantor Fitzgerald.
January 24 2017
Amedica Corporation announced the closing of their Confidentially Marketed Public Offering in the amount of $4,500,000. EG&S acted as counsel to Maxim Group.
January 24 2017
EGS assisted PhotoMedex, Inc. in its sale of substantially all of its assets primarily related to or used in the company’s consumer products division, including its no!no!® hair and skin products and the Kyrobak back pain management products.
The gross proceeds receivable by the company were up to $5M. In addition, the company entered into a royalty agreement with the purchaser.
January 24 2017
Can-Fite Biopharma Ltd. announced the closing of their Registered Direct offering in the amount of $5,000,000. EG&S acted as counsel to the Placement Agent.